Cargando…

Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Eribulin is a recommended treatment option for locally advanced or metastatic breast cancer (LABC/MBC) in adults whose disease has progressed after at least two chemotherapy regimens. The National Institute for Health and Care Excellence (NICE) invited the manufacturer of eribulin (Halaven(®); Eisai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleeman, Nigel, Bagust, Adrian, Duarte, Rui, Richardson, Marty, Nevitt, Sarah, Boland, Angela, Kotas, Eleanor, McEntee, Joanne, Thorp, Nicky
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710448/ https://www.ncbi.nlm.nih.gov/pubmed/30742256 http://dx.doi.org/10.1007/s41669-018-0114-z

Ejemplares similares

Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Lambe, Tosin, et al.
Publicado: (2018)

Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Houten, Rachel, et al.
Publicado: (2020)

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Bresnahan, Rebecca, et al.
Publicado: (2023)

Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Stainthorpe, Angela, et al.
Publicado: (2018)

Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Stainthorpe, Angela, et al.
Publicado: (2020)

Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Houten, Rachel, et al.
Publicado: (2023)

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
por: Dickson, Rumona, et al.
Publicado: (2018)

A systematic review of health state utility values for thyroid cancer
por: Houten, Rachel, et al.
Publicado: (2020)

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal
por: Greenhalgh, Janette, et al.
Publicado: (2013)

Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: A systematic review and economic evaluation
por: Duarte, Rui, et al.
Publicado: (2019)

A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
por: Fleeman, Nigel, et al.
Publicado: (2019)

The impact of rarity in NICE’s health technology appraisals
por: Clarke, Sophie, et al.
Publicado: (2021)

A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process
por: Kaltenthaler, Eva C, et al.
Publicado: (2012)

Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
por: Hashem, Ferhana, et al.
Publicado: (2017)

Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2017)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

External validity of rct evidence in cost-effectiveness analyses. A review of recent technology appraisals for nice and proposed methods of adjustment
por: Mantopoulos, Theodoros, et al.
Publicado: (2015)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2016)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias
por: Brown, Patrick, et al.
Publicado: (2011)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Wijnen, Ben, et al.
Publicado: (2022)

Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
por: Osipenko, Leeza
Publicado: (2021)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis
por: Cortes, Javier, et al.
Publicado: (2019)

Anthropometric Variables Accurately Predict Dual Energy X-Ray Absorptiometric-Derived Body Composition and Can Be Used to Screen for Diabetes
por: Yavari, Reza, et al.
Publicado: (2011)

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

It’s not evidence, it’s insight: bringing patients’ perspectives into health technology appraisal at NICE
por: Staley, Kristina, et al.
Publicado: (2016)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
por: Doherty, Mark K, et al.
Publicado: (2015)

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Reproductive pathology of domestic mammals /
por: McEntee, Kenneth
Publicado: (1990)

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process
por: Walton, M. J., et al.
Publicado: (2019)

The Challenges of Measuring and Valuing Quality of Life in Preschool Children: A Retrospective Review of NICE Appraisals
por: Lamb, Alan, et al.
Publicado: (2021)

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
por: Muñoz-Couselo, Eva, et al.
Publicado: (2011)

Oncology Nursing Support for Safe and Effective Use of Eribulin in Metastatic Breast Cancer
por: Donovan, Diana, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kj53kkpbpon5hmc0u5atr92jdt